The use of complementary and alternative medicine by patients with cancer: a cross-sectional survey in Saudi Arabia.
Identifieur interne : 000973 ( PubMed/Curation ); précédent : 000972; suivant : 000974The use of complementary and alternative medicine by patients with cancer: a cross-sectional survey in Saudi Arabia.
Auteurs : Khadega A. Abuelgasim [Arabie saoudite] ; Yousef Alsharhan [Arabie saoudite] ; Tariq Alenzi [Arabie saoudite] ; Abdulaziz Alhazzani [Arabie saoudite] ; Yosra Z. Ali [Arabie saoudite] ; Abdul Rahman Jazieh [Arabie saoudite]Source :
- BMC complementary and alternative medicine [ 1472-6882 ] ; 2018.
Descripteurs français
- KwdFr :
- MESH :
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Complementary Therapies (statistics & numerical data), Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Neoplasms (epidemiology), Neoplasms (therapy), Patients (statistics & numerical data), Prevalence, Saudi Arabia (epidemiology), Surveys and Questionnaires, Young Adult.
- MESH :
- epidemiology : Neoplasms, Saudi Arabia.
- statistics & numerical data : Complementary Therapies, Patients.
- therapy : Neoplasms.
- Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Prevalence, Surveys and Questionnaires, Young Adult.
Abstract
A significant proportion of cancer patients use complementary and alternative medicine (CAM) along with conventional therapies (CT), whereas a smaller proportion delay or defer CT in favor of CAM. Previous studies exploring CAM use among cancer patients in the Middle East region have shown discrepant results. This study investigates the prevalence and pattern of CAM use by Saudi cancer patients. It also discusses the possible benefits and harm related to CAM use by cancer patients, and it explores the beliefs patients hold and their transparency with health care providers regarding their CAM use.
DOI: 10.1186/s12906-018-2150-8
PubMed: 29530034
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000973
Links to Exploration step
pubmed:29530034Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of complementary and alternative medicine by patients with cancer: a cross-sectional survey in Saudi Arabia.</title><author><name sortKey="Abuelgasim, Khadega A" sort="Abuelgasim, Khadega A" uniqKey="Abuelgasim K" first="Khadega A" last="Abuelgasim">Khadega A. Abuelgasim</name><affiliation wicri:level="1"><nlm:affiliation>King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ahmedkh1@ngha.med.sa.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alsharhan, Yousef" sort="Alsharhan, Yousef" uniqKey="Alsharhan Y" first="Yousef" last="Alsharhan">Yousef Alsharhan</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alenzi, Tariq" sort="Alenzi, Tariq" uniqKey="Alenzi T" first="Tariq" last="Alenzi">Tariq Alenzi</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alhazzani, Abdulaziz" sort="Alhazzani, Abdulaziz" uniqKey="Alhazzani A" first="Abdulaziz" last="Alhazzani">Abdulaziz Alhazzani</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Ali, Yosra Z" sort="Ali, Yosra Z" uniqKey="Ali Y" first="Yosra Z" last="Ali">Yosra Z. Ali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Ministry of National Guards, King Abdulaziz Medical City, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Oncology, Ministry of National Guards, King Abdulaziz Medical City, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Jazieh, Abdul Rahman" sort="Jazieh, Abdul Rahman" uniqKey="Jazieh A" first="Abdul Rahman" last="Jazieh">Abdul Rahman Jazieh</name><affiliation wicri:level="1"><nlm:affiliation>King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29530034</idno><idno type="pmid">29530034</idno><idno type="doi">10.1186/s12906-018-2150-8</idno><idno type="wicri:Area/PubMed/Corpus">000973</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000973</idno><idno type="wicri:Area/PubMed/Curation">000973</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000973</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The use of complementary and alternative medicine by patients with cancer: a cross-sectional survey in Saudi Arabia.</title><author><name sortKey="Abuelgasim, Khadega A" sort="Abuelgasim, Khadega A" uniqKey="Abuelgasim K" first="Khadega A" last="Abuelgasim">Khadega A. Abuelgasim</name><affiliation wicri:level="1"><nlm:affiliation>King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ahmedkh1@ngha.med.sa.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alsharhan, Yousef" sort="Alsharhan, Yousef" uniqKey="Alsharhan Y" first="Yousef" last="Alsharhan">Yousef Alsharhan</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alenzi, Tariq" sort="Alenzi, Tariq" uniqKey="Alenzi T" first="Tariq" last="Alenzi">Tariq Alenzi</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Alhazzani, Abdulaziz" sort="Alhazzani, Abdulaziz" uniqKey="Alhazzani A" first="Abdulaziz" last="Alhazzani">Abdulaziz Alhazzani</name><affiliation wicri:level="1"><nlm:affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Saud bin Abdulaziz University for Health Sciences, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Ali, Yosra Z" sort="Ali, Yosra Z" uniqKey="Ali Y" first="Yosra Z" last="Ali">Yosra Z. Ali</name><affiliation wicri:level="1"><nlm:affiliation>Department of Oncology, Ministry of National Guards, King Abdulaziz Medical City, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>Department of Oncology, Ministry of National Guards, King Abdulaziz Medical City, Riyadh</wicri:regionArea></affiliation></author><author><name sortKey="Jazieh, Abdul Rahman" sort="Jazieh, Abdul Rahman" uniqKey="Jazieh A" first="Abdul Rahman" last="Jazieh">Abdul Rahman Jazieh</name><affiliation wicri:level="1"><nlm:affiliation>King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.</nlm:affiliation><country xml:lang="fr">Arabie saoudite</country><wicri:regionArea>King Abdullah International Medical Research Center, Riyadh</wicri:regionArea></affiliation></author></analytic><series><title level="j">BMC complementary and alternative medicine</title><idno type="eISSN">1472-6882</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Complementary Therapies (statistics & numerical data)</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasms (epidemiology)</term><term>Neoplasms (therapy)</term><term>Patients (statistics & numerical data)</term><term>Prevalence</term><term>Saudi Arabia (epidemiology)</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Arabie saoudite (épidémiologie)</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Patients ()</term><term>Prévalence</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thérapies complémentaires ()</term><term>Tumeurs ()</term><term>Tumeurs (épidémiologie)</term><term>Études transversales</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Neoplasms</term><term>Saudi Arabia</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Complementary Therapies</term><term>Patients</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Arabie saoudite</term><term>Tumeurs</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cross-Sectional Studies</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Patients</term><term>Prévalence</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Thérapies complémentaires</term><term>Tumeurs</term><term>Études transversales</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A significant proportion of cancer patients use complementary and alternative medicine (CAM) along with conventional therapies (CT), whereas a smaller proportion delay or defer CT in favor of CAM. Previous studies exploring CAM use among cancer patients in the Middle East region have shown discrepant results. This study investigates the prevalence and pattern of CAM use by Saudi cancer patients. It also discusses the possible benefits and harm related to CAM use by cancer patients, and it explores the beliefs patients hold and their transparency with health care providers regarding their CAM use.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29530034</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1472-6882</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Mar</Month><Day>12</Day></PubDate></JournalIssue><Title>BMC complementary and alternative medicine</Title><ISOAbbreviation>BMC Complement Altern Med</ISOAbbreviation></Journal><ArticleTitle>The use of complementary and alternative medicine by patients with cancer: a cross-sectional survey in Saudi Arabia.</ArticleTitle><Pagination><MedlinePgn>88</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12906-018-2150-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">A significant proportion of cancer patients use complementary and alternative medicine (CAM) along with conventional therapies (CT), whereas a smaller proportion delay or defer CT in favor of CAM. Previous studies exploring CAM use among cancer patients in the Middle East region have shown discrepant results. This study investigates the prevalence and pattern of CAM use by Saudi cancer patients. It also discusses the possible benefits and harm related to CAM use by cancer patients, and it explores the beliefs patients hold and their transparency with health care providers regarding their CAM use.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cross-sectional study was conducted in oncology wards and outpatient clinics by using face-to-face interviews with the participants.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 156 patients with a median age of 50 years (18-84) participated in the study. The prevalence of CAM use was 69.9%; the most prominent types of CAM were those of a religious nature, such as supplication (95.4%), Quran recitation (88.1%), consuming Zamzam water (84.4%), and water upon which the Quran has been read (63.3%). Drinking camel milk was reported by 24.1% of CAM users, whereas camel urine was consumed by 15.7%. A variety of reasons were given for CAM use: 75% reported that they were using CAM to treat cancer, enhance mood (18.3%),control pain (11.9%), enhance the immune system (11%),increase physical fitness (6.4%), and improve appetite (4.6%). Thirty percent of CAM users had discussed the issue with their doctors; only 7.7% had done so with their nurses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The use of CAM, including camel products, is highly prevalent among cancer patients in the Middle East, but these patients do not necessarily divulge their CAM use to their treating physicians and nurses. Although CAM use can be beneficial, some can be very harmful, especially for cancer patients. Association is known between camel products and brucellosis and Middle East respiratory syndrome coronavirus (MERS-CoV). Both can lead to tremendous morbidity in immune-compromised patients. Doctor-patient communication regarding CAM use is of paramount importance in cancer care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abuelgasim</LastName><ForeName>Khadega A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>King Abdullah International Medical Research Center, Riyadh, Saudi Arabia. ahmedkh1@ngha.med.sa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Ministry of National Guards, King Abdulaziz Medical City, Riyadh, Saudi Arabia. ahmedkh1@ngha.med.sa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alsharhan</LastName><ForeName>Yousef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alenzi</LastName><ForeName>Tariq</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alhazzani</LastName><ForeName>Abdulaziz</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ali</LastName><ForeName>Yosra Z</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>Department of Oncology, Ministry of National Guards, King Abdulaziz Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jazieh</LastName><ForeName>Abdul Rahman</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>King Abdullah International Medical Research Center, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oncology, Ministry of National Guards, King Abdulaziz Medical City, Riyadh, Saudi Arabia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Complement Altern Med</MedlineTA><NlmUniqueID>101088661</NlmUniqueID><ISSNLinking>1472-6882</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000529" MajorTopicYN="N">Complementary Therapies</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010361" MajorTopicYN="N">Patients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012529" MajorTopicYN="N">Saudi Arabia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Brucellosis</Keyword><Keyword MajorTopicYN="N">Camel products</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Complementary and alternative medicine</Keyword><Keyword MajorTopicYN="N">Middle East respiratory syndrome coronavirus (MERS-CoV)</Keyword><Keyword MajorTopicYN="N">Religious belief</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29530034</ArticleId><ArticleId IdType="doi">10.1186/s12906-018-2150-8</ArticleId><ArticleId IdType="pii">10.1186/s12906-018-2150-8</ArticleId><ArticleId IdType="pmc">PMC5848536</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>East Mediterr Health J. 2003 Jan-Mar;9(1-2):99-107</Citation><ArticleIdList><ArticleId IdType="pubmed">15562738</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2017 Apr 20;35(12 ):1341-1367</Citation><ArticleIdList><ArticleId IdType="pubmed">28148207</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 2002 Oct;92(10):1606-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12356606</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Cancer Prev. 2004 Jan-Mar;5(1):3-14</Citation><ArticleIdList><ArticleId IdType="pubmed">15074998</ArticleId></ArticleIdList></Reference><Reference><Citation>J Altern Complement Med. 2012 Nov;18(11):1045-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22906212</ArticleId></ArticleIdList></Reference><Reference><Citation>Euro Surveill. 2014 Jun 12;19(23 ):null</Citation><ArticleIdList><ArticleId IdType="pubmed">24957745</ArticleId></ArticleIdList></Reference><Reference><Citation>Integr Med Insights. 2008;3:1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">21614154</ArticleId></ArticleIdList></Reference><Reference><Citation>N Z Med J. 2003 Jan 24;116(1168):U296</Citation><ArticleIdList><ArticleId IdType="pubmed">12601420</ArticleId></ArticleIdList></Reference><Reference><Citation>J Family Community Med. 2000 May;7(2):17-25</Citation><ArticleIdList><ArticleId IdType="pubmed">23008618</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Microbiol. 1987 Aug;25(8):1384-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3624438</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Sci Tech. 2010 Dec;29(3):663-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21309464</ArticleId></ArticleIdList></Reference><Reference><Citation>Saudi Pharm J. 2017 Mar;25(3):306-318</Citation><ArticleIdList><ArticleId IdType="pubmed">28344484</ArticleId></ArticleIdList></Reference><Reference><Citation>J Altern Complement Med. 2004 Jun;10(3):560-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15253863</ArticleId></ArticleIdList></Reference><Reference><Citation>Integr Cancer Ther. 2005 Dec;4(4):274-86</Citation><ArticleIdList><ArticleId IdType="pubmed">16282504</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2012 Oct;66(10):924-39</Citation><ArticleIdList><ArticleId IdType="pubmed">22994327</ArticleId></ArticleIdList></Reference><Reference><Citation>Oncologist. 2004;9(1):80-9</Citation><ArticleIdList><ArticleId IdType="pubmed">14755017</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepatology. 2014 Oct;60(4):1399-408</Citation><ArticleIdList><ArticleId IdType="pubmed">25043597</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Saudi Med. 2013 May-Jun;33(3):282-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23793433</ArticleId></ArticleIdList></Reference><Reference><Citation>J Cancer Res Clin Oncol. 2013 Sep;139(9):1515-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23832609</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Oncol. 2004 Jun 15;22(12):2489-503</Citation><ArticleIdList><ArticleId IdType="pubmed">15197212</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Med (Lond). 2013 Apr;13(2):126-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23681857</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2017 Jun 1;215(11):1702-1705</Citation><ArticleIdList><ArticleId IdType="pubmed">28387845</ArticleId></ArticleIdList></Reference><Reference><Citation>P T. 2010 Oct;35(10):570-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21037910</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Complement Altern Med. 2016 Jul 07;16:192</Citation><ArticleIdList><ArticleId IdType="pubmed">27389194</ArticleId></ArticleIdList></Reference><Reference><Citation>Asian Pac J Cancer Prev. 2014;15(6):2547-54</Citation><ArticleIdList><ArticleId IdType="pubmed">24761862</ArticleId></ArticleIdList></Reference><Reference><Citation>Prev Vet Med. 2002 Sep 10;55(1):47-56</Citation><ArticleIdList><ArticleId IdType="pubmed">12324206</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000973 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000973 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:29530034
|texte= The use of complementary and alternative medicine by patients with cancer: a cross-sectional survey in Saudi Arabia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:29530034" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |